----item----
version: 1
id: {F87BDD1D-5824-4C1E-AE1A-5D3D3054AF7F}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/07/07/PharmAsia News business bulletin
parent: {CC2443D4-0E6D-4729-AC39-BFE81987180B}
name: PharmAsia News business bulletin
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 8a5d103c-1f9d-4a3e-bcd3-089ede656aaa

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 32

PharmAsia News business bulletin
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 32

PharmAsia News business bulletin
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 5840

<p>A new regular roundup of commercial stories appearing in <i>Scrip</i>'s sister publication PharmAsia News, whose multilingual team of regional experts provide authoritative business intelligence focused on the Asian marketplace.</p><p>Full stories can be accessed by clicking on the story title (subscription required).</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/8/nepstar-going-private-as-china-meltdown-creates-relisting-uncertainty" target="_new">Nepstar Going Private As Wider China Meltdown Creates Relisting Uncertainties</a></p><p>Another US-listed Chinese healthcare firm is going private on the heels of Mindray, Wuxi, and China Cord Blood. But the current severe turbulence in China's stock markets could complicate the prospects of relisting for other companies that have already taken this route and may be looking at re-offering their shares.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/8/australian-industry-to-publicly-disclose-individual-payments" target="_new">Australian Industry To Publicly Disclose Individual Payments</a></p><p>The main pharmaceutical industry association in Australia has adopted new measures on the transparency of payments to healthcare professionals that will come into effect in October under an updated Code of Conduct designed in large part to ensure public trust.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/9/more-govt-support-for-pharma-as-korea-plans-new-fund" target="_new">More Govt Support For Pharma As Korea Plans New Fund</a></p><p>Following the successful launch of pharma development funds in the past few years, South Korea's health ministry is planning to create a new fund this year to further support domestic pharma firms' efforts to enter overseas markets and spur private sector investment in the broader healthcare industry.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/7/9/doors-close-and-open-for-oramed-in-china-diabetes-market" target="_new">Doors Close And Open For Oramed In China Diabetes Market</a></p><p>An intended licensing agreement between Wuzhou Zhongheng Group and Oramed for diabetes drugs may have fallen apart, but Zhongheng will continue to acquire new products abroad as part of its development strategy, while Oramed has tied up with another partner in the large and growing Chinese diabetes market, which has already attracted many multinationals.</p><p><p><a href="https://www.pharmamedtechbi.com/Publications/Pharmasia-News/2015/7/6/Samsung-Affiliates-Aim-For-IPO-Biologics-Expansion" target="_new">Samsung Affiliates Aim For IPO, Biologics Expansion</a></p><p>Samsung Group's two biopharma affiliates are aiming high to become global leaders in the development of biosimilars and production of biomedicines. Although the largest South Korean conglomerate is a late starter compared with other biosimilar rivals including Celltrion, its affiliates Samsung Bioepis and Samsung Biologics have been making rapid progress on the back of strong group-wide support. </p><p><p><a href="https://www.pharmamedtechbi.com/Publications/Pharmasia-News/2015/7/6/LowCost-HIV-Alliance-To-Restore-GSKs-China-Image" target="_new">Low-Cost HIV Alliance To Restore GSK's China Image?</a></p><p>Although it is still awaiting approval from the China FDA for its widely-sold and fast-growing HIV drug, GSK unit ViiV has inked a deal with a Chinese firm to manufacture low-priced Tivicay in the country. The arrangement could be a pre-emptive move as China is increasing pressure on the prices of costly new therapies for infectious diseases. </p><p><p><a href="https://www.pharmamedtechbi.com/Publications/Pharmasia-News/2015/7/7/BioBay-Center-To-Help-MedTech-Firms-Enter-China" target="_new">BioBay Center To Help Medtech Firms Enter China</a></p><p>With the aim of helping western companies tap into the fast-growing Chinese healthcare market, a new cross-border medical technology commercialization center planned in the Suzhou BioBay cluster will provide funding and assistance to selected US and European companies for all aspects of product registration and commercialization in China. </p><p><p><a href="https://www.pharmamedtechbi.com/Publications/Pharmasia-News/2015/7/7/Samsungs-Humira-Biosimilar-Set-For-Filings-As-It-Completes-Phase-III" target="_new">Samsung's Humira Biosimilar Set For Filings As It Completes Phase III</a></p><p>The Samsung Group's biopharmaceutical affiliate Samsung Bioepis has successfully completed Phase III global clinical trials for its biosimilar version of Humira, taking another step forward in its ambitions to become a global leader in the development of biosimilars. </p><p><p><a href="https://www.pharmamedtechbi.com/Publications/Pharmasia-News/2015/7/8/Turkey-Euro-Change-Too-Little-Too-Late-For-Pharma" target="_new">Turkey Euro Change Too Little, Too Late For Pharma?</a></p><p>After years of pressure by the industry and a supporting court decision, the Turkish government has finally fixed a new euro exchange rate for the pharma industry. But the modest revision has been criticized as too little, too late and far from being a long-term solution for firms operating in the country. </p><p><p><a href="https://www.pharmamedtechbi.com/Publications/Pharmasia-News/2015/7/5/Chinas-mHealth-Industry--A-Bubble-Waiting-To-Burst?" target="_new">China's mHealth Industry &ndash; A Bubble Waiting To Burst?</a></p><p>In the Chinese internet industry, one of the most heard buzzwords at the moment is mHealth (mobile health). The number of mHealth Apps in the country is already staggering, with 5,000 predicted to be available by the end of 2015, versus just 2,000 in 2013. But is the field already a bubble preparing to burst given underlying challenges? </p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 235

<p>A new regular roundup of commercial stories appearing in <i>Scrip</i>'s sister publication PharmAsia News, whose multilingual team of regional experts provide authoritative business intelligence focused on the Asian marketplace.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 32

PharmAsia News business bulletin
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150707T165420
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150707T165420
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150707T165420
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029199
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 32

PharmAsia News business bulletin
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{DB39CCA6-EB88-422C-8247-AB4AD01491E2}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 13

Headline News
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

359288
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042420Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

8a5d103c-1f9d-4a3e-bcd3-089ede656aaa
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042420Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
